MALAKOFF, 8 February 2016 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces that 3 patients have recently been treated at the London Echotherapy Center located in the London Breast Clinic, London, England. Treated for symptomatic fibroadenomas, the patients were the first to benefit from echotherapy in the UK. Theraclion also announces the persistence of observed fibroadenoma volume reduction after treatment with Echopulse at the 3-year follow-up. Data were generated as part of an international clinical study led by the University of Sofia, Bulgaria.

The recently created London Echotherapy Center has acquired an Echopulse system to treat breast fibroadenoma and benign thyroid nodules. The center is led by two internationally renowned clinicians, Mr. Richard Sainsbury (Surgeon) and Dr. William Teh (Radiologist). The center is based in the prestigious 108 Harley Street Medical Chambers which, among other specialty centers, incorporates the London Breast Clinic. The center provides a full range of integrated breast care services for both benign and malignant diseases, including screening, surgery, radiotherapy, chemotherapy, reconstruction and after care.

“We are proud to pioneer the first Echotherapy Center in the UK,” says Richard Sainsbury, breast surgeon and co-director of the London Echotherapy Center. “Providing non-invasive solutions for our patients is a revolutionizing innovation.”

“Harley Street is a strategic location for us to start a UK Echotherapy service,” explains David Caumartin, CEO of Theraclion. “The London Breast Clinic is of international reputation and both physicians are nationally and internationally recognized clinical experts in their respective field of expertise. Both clinicians also work within the NHS and will actively spread the message of the availability of the new technology to a wider clinical community within the UK.”

The London Echotherapy Center is one of the 16 centers developed within the last three years to offer echotherapy to patients in routine clinical practice, highlighting the growing interest of healthcare specialists in this new non-invasive alternative.

Michel Nuta, CMO at Theraclion, says, "This increased acceptance of the technique is - among other factors - explained by the persistence and durability of the results we see in patients in the 3 years following the procedure, as shown in the international clinical study of the University of Sofia. In those patients, a sustained 80% volume reduction after treatment with Echopulse has been observed at three years with no reported cases of recurrences."

About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high- intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 30 people, 53 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

More HCB News